In the News

Dr. Rollie Carlson was interviewed for Docwire News

Interview with DocWireNew: Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis

DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment. https://youtu.be/Vd0FL3fYPwY
Drug Target Review screenshot

Interview with Dr Rolland Carlson and Dr Richard Brandon

Download the Drug Target Review interview with Dr. Rolland Carlson and Dr. Richard Brandon.(pdf) The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular...
Technology Networks

A Paradigm Shift in Sepsis Diagnostics

By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the...
Med Device Online

Tips For Obtaining Your 510(k) FDA Clearance

By Rolland Carlson, Ph.D., CEO, Immunexpress Our SeptiCyte RAPID clinical test received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. Sepsis is a life-threatening medical condition. Every minute counts for these patients in the ER and ICU. Clinicians in these settings need processes to distinguish sepsis patients...
DNAweekly-listed-at-OnGenealogy

DNA Weekly: Discussing Sepsis Diagnosis with Immunexpress

Immunexpress is a molecular diagnostic company focused on improving outcomes for suspected sepsis patients. In this interview CEO Dr. Rollie Carlson discusses the company’s FDA-cleared sepsis diagnostic test and the value it brings to the healthcare system.
10News Brisbane

10News Brisbane

SeptiCyte RAPID is highlighted in this 10News First Brisbane interview. The country's largest pediatric sepsis study at the Queensland Children's Hospital is working on finding simple diagnostic blood tests for the 5,000 Australians a year and robs others of their limbs.
MedTech Gurus

Finding The Product- Market Fit, with Rollie Carlson Ph.D. CEO of Immunexpress

Gurus, why should you have your engineers and researchers out in the field? How can they get a good product-market fit? What is the NOT INVENTED HERE factor and why should you avoid it? Dr. Carlson discusses this and more. Listen in as he provides further evidence that perfect should...
MedTech Insight

Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market

Executive Summary Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
SCCM

SCCM Podcast: Severe COVID-19 and Sepsis

Severe COVID-19 infection can be a form of viral sepsis with occasionally concomitant bacterial infection. Pamela M. Peeke MD, MPH, FACP, FACSM, is joined by Russell Miller, MD, MPH, FCCM, to discuss the definition of sepsis and overlap with case descriptions of patients with severe COVID-19, how experience with viral...
Medical Plastic News

Biocartis announces market release of SeptiCyte RAPID test on Idylla

Biocartis Group has released of SeptiCyte RAPID on Idylla as a CE-marked IVD test. SeptiCyte RAPID is a host-response test that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and provides actionable results in about one hour.
MedTech Innovation

Q&A: Sepsis detection technology that can triage COVID-19 patients

Ian Bolland caught up with Dr. Rolland Carlson, CEO of Immunexpress, to talk about a molecular diagnostic, SeptiCyte RAPID, which is used to detect sepsis and offers the potential to triage severe COVID-19 patients in the emergency department. Expand Briefly, tell us more about Immunexpress – how did the idea...
360DX

Immunexpress, Biocartis to Roll Out Sepsis Test in Europe Ahead of Planned US Launch

Immunexpress and its partner Biocartis plan to introduce a new, rapid test for sepsis in Europe this quarter ahead of a potential US Food and Drug Administration 510(k) clearance for the assay later this year. The companies are positioning the test, called SeptiCyte Rapid, to triage COVID-19 patients who could...